Tomasz Masior - Clinical Trial Investigator | Syfrah

Trials Sponsors Conditions Drugs Pricing

Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(12)

MIXED(1)

phase_1phase_2phase_3

glypharma-therapeutics

FE203799 GLP-2 analogue

glypharma-therapeutics

glypharma-therapeutics

FE203799 Placebo GLP-2 analogue

glypharma-therapeutics

6 unique interventions2 categories

Analytics

Trial Phases

Phase 17

Phase 25

Phase 32

Trial Status

Completed8

Terminated1

Other2

Role Distribution

Other Roles11

Activity Timeline

Clinical Trials (11)

NCT06002555Phase 1Completed

Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation

Healthy Subjects

StudydirectorStart date: 2023-05-23

NCT05995704Phase 1Completed

Evaluation of Apraglutide on Gastric Emptying

Healthy Subjects

StudydirectorStart date: 2023-03-02

NCT05706623Phase 1Completed

A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

StudydirectorStart date: 2023-01-30

NCT05415410Phase 2Terminated

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

GVHD

StudydirectorStart date: 2022-05-25

NCT05018286Phase 3Active Not Recruiting

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

Short Bowel Syndrome

StudydirectorStart date: 2021-07-13

NCT04964986Phase 2Completed

Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

Short Bowel Syndrome

StudydirectorStart date: 2021-06-14

NCT04627025Phase 3Completed

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

Short Bowel Syndrome

StudydirectorStart date: 2021-01-26

NCT04699032Phase 1Completed

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

Chronic Kidney Disease

StudydirectorStart date: 2020-12-08

NCT03415594Phase 1/2Completed

Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

Short Bowel Syndrome

StudydirectorStart date: 2018-05-08

NCT03408132Phase 1/2Completed

Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency

SBS - Short Bowel Syndrome

StudydirectorStart date: 2018-05-02

Showing 10 of 11 trials

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

CO

High-influence Collaborator

CO

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Short Bowel Syndrome4 Healthy Volunteers2 Acute graft versus host disease (aGvHD)1 Chronic Kidney Diseases1 GVHD1 Healthy1 Hepatic Impairment1 Lymphoma, Hodgkin's, Adult1

Affiliations

VectivBio AG

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Hagop Youssoufian, MD

Verastem, Inc.

Shared therapeutic areas:

HealthyHealthy VolunteersHepatic Impairment

Similarity Score9%

Suman Wason, MD

Lexicon Pharmaceuticals, Inc.

Shared therapeutic areas:

HealthyHepatic ImpairmentChronic Kidney Diseases

Similarity Score9%

Suman Sheraz, PhD*

Riphah International University

Shared therapeutic areas:

HealthyHealthy Volunteers

Similarity Score6%

Jack A Yanovski, M.D.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Shared therapeutic areas:

Healthy VolunteersHealthy

Similarity Score6%

General Manager

Tanabe Pharma Corporation

Shared therapeutic areas:

HealthyHealthy Volunteers

Similarity Score6%

Melda Saglam, PhD

Hacettepe University

Shared therapeutic areas:

Chronic Kidney DiseasesHealthy

Similarity Score6%

Robert B Innis, M.D.

National Institute of Mental Health (NIMH)

Shared therapeutic areas:

HealthyHealthy Volunteers

Similarity Score6%

Mikhail Samsonov

R-Pharm

Shared therapeutic areas:

HealthyHepatic Impairment

Similarity Score6%

Mark Hallett, M.D.

National Institute of Neurological Disorders and Stroke (NINDS)

Shared therapeutic areas:

Healthy VolunteersHealthy

Similarity Score6%

Britt Burton-Freeman, ph.D

Illinois Institute of Technology

Shared therapeutic areas:

HealthyHealthy Volunteers

Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (11)

Showing 11 of 11 trials

NCT06002555Phase 1StudyDirector

Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation

Healthy Subjects

Completed

NCT05995704Phase 1StudyDirector

Evaluation of Apraglutide on Gastric Emptying

Healthy Subjects

Completed

NCT05706623Phase 1StudyDirector

A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Completed

NCT05415410Phase 2StudyDirector

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

GVHD

Terminated

NCT05018286Phase 3StudyDirector

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

Short Bowel Syndrome

Active Not Recruiting

NCT04964986Phase 2StudyDirector

Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

Short Bowel Syndrome

Completed

NCT04627025Phase 3StudyDirector

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

Short Bowel Syndrome

Completed

NCT04699032Phase 1StudyDirector

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

Chronic Kidney Disease

Completed

NCT03415594Phase 1/2StudyDirector

Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

Short Bowel Syndrome

Completed

NCT03408132Phase 1/2StudyDirector

Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency

SBS - Short Bowel Syndrome

Completed

NCT03417765Phase 1/2StudyDirector

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

Lymphoma, Hodgkin's, AdultLymphoma, Non-Hodgkin's, Adult

Withdrawn

All 11 trials loaded